Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

Abstract: The present disclosure provides a method of detecting IgG4 and Smad1 in a biological sample from a subject with onset or a risk of onset of diabetic nephropathy.

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

Abstract: A detection reagent for comprehensively detecting an oxidized state and a glycated state of a low-density lipoprotein. While an oxidized low-density lipoprotein and a glycated low-density lipoprotein are detected with a fluolophore-labelled antibody, a lipid radical is detected with a fluorescent nitroxide 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-oxyl (NBD-Pen).

Abstract: The present invention provides a test method which enables specific diagnosis of early-stage pathology of diabetic nephropathy. There is provided a method of detecting onset or a risk of onset of diabetic nephropathy, comprising measuring IgG4 in a biological sample derived from a subject. This method may further comprise measuring Smad1 in the biological sample derived from the subject. Preferably, both IgG4 and Smad1 are measured.

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof

Abstract: A detection reagent for comprehensively detecting an oxidized state and a glycated state of a low-density lipoprotein. While an oxidized low-density lipoprotein and a glycated low-density lipoprotein are detected with a fluolophore-labelled antibody, a lipid radical is detected with a fluorescent nitroxide 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-oxyl (NBD-Pen).

Abstract: Two genes implicated in arteriosclerotic diseases such as cerebral infarction were successfully identified by performing genome-wide correlation studies using SNPs by targeting the entire genome. Polymorphic mutations that can be used to examine the presence or absence of risk factors for arteriosclerotic diseases were successfully found on the genes. Subjects can be efficiently examined for the presence or absence of risk factors for arteriosclerotic diseases using the presence or absence of the polymorphic mutations as indicators. Furthermore, methods of screening for therapeutic agents for arteriosclerotic diseases are enabled by using expression or function of the genes as index.